PER
Click for more information
2.38% 8.2¢ percheron therapeutics limited

Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations, page-3

  1. markie125
    7,434 Posts.
    lightbulb Created with Sketch. 532
    clock Created with Sketch.
    21/05/20
    18:56
    Post #: 44759387
    No news yet on the approval or European phase 2b been granted or anything on those line.
    just data
    ANP Price at posting: 4.8¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 2  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

IMU Imugene doses first cancer patient in Oasis trial
right-arrow Created with Sketch.
MYR Myer lobs proposed merger at major shareholder Premier Investments
right-arrow Created with Sketch.
GWR Scoping study and Phase 2 drilling progress Prospect Ridge magnesium play for GWR
right-arrow Created with Sketch.
CTT Cettire has launched in China – but can it turn its share price around?
right-arrow Created with Sketch.
NEWS Money and Investing: Talking the minefield of divorce & family law
right-arrow Created with Sketch.
HMD HeraMED delivers digital maternity care to select clinics with Telstra
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.2¢ 		Change
-0.002(2.38%) 		Mkt cap ! $73.92M
Open High Low Value Volume
8.2¢ 8.2¢ 8.1¢ $24.83K 304.8K

Buyers (Bids)

No. Vol. Price($)
1 61071 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 21678 1
View Market Depth
Last trade - 16.10pm 26/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.